ReviewFrontiers in oncology2024
Diagnosis progress of carcinoma of unknown primary.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ARID1A-Deficient and 11q13-Amplified Metastatic Pancreatic Cancer Initially Presenting as Retroperitoneal Fibrosis in a Patient with Familial CHEK2 Variant.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carcinoma of unknown primary (CUP) is a common and complex type of tumor in clinical practice, where the primary site cannot be determined through conventional diagnostic methods, posing significant challenges for clinical diagnosis and treatment. In recent years, advancements in gene expression profiling and genetic testing technologies have provided new perspectives for CUP research, driving progress in this field. By analyzing gene expression profiles, researchers can more effectively identify the tissue origin of tumors, thereby improving diagnostic accuracy. At the same time, the potential application of genetic testing is continuously being explored, offering new possibilities for personalized treatment. This article aims to discuss the latest advancements in the diagnosis of CUP, analyze the importance of gene expression profiling and genetic testing in tumor origin identification and their clinical applications, and summarize current research progress and future research directions, with the goal of providing a theoretical basis for the early diagnosis and treatment of CUP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.